Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357901 · ClinicalTrials.gov registry record · Phase 3
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
A Phase 3 study of Opioid-Related Disorders and Opioid Dependence, sponsored by Indivior.
- Completed
- Registry status
- Phase 3
- Development phase
- 665
- Enrollment target
- 20
- Study locations
NCT02357901 is a Phase 3 study of Opioid-Related Disorders and Opioid Dependence that has completed, run by Indivior. The registered enrollment target is 665 participants, above the 333-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT02357901, a Phase 3 study of Opioid-Related Disorders and Opioid Dependence, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 665 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo controlled, multicenter study in male and female participants who are seeking treatment for opioid use disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RBP-6000
- DRUG SUBOXONE
Study Locations (20)
California
- Collaborative Neuroscience Network - Garden Grove
- Behavioral Research Specialists - Glendale
- Synergy Clinical Research Center - National City
- North County Clinical Research - Oceanside
- Artemis Institute for Clinical Research - San Diego
- Care Practice - San Francisco
- Southern California Research - Thousand Oaks
Florida
- Amit Vijapura - Jacksonville
- Meridien Research - Lakeland
- Innovative Clinical Research - Lauderhill
- Florida Clinical Research Center - Maitland
- Try Research - Maitland
- Scientific Clinical Research - North Miami
- Research Centers of America - Oakland Park
Alabama
- Haleyville Clinical Research - Haleyville
- Boyett Health Services - Hamilton
Arkansas
- Woodland International Research Group - Little Rock
Illinois
- Behavioral Health Care Associates - Schaumburg
Kansas
- Phoenix Medical Research - Prairie Village
Louisiana
- Louisiana Research Associates - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2015-01-28 |
| Est. Completion | 2016-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02357901
The ClinicalTrials.gov registry entry for NCT02357901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 665 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 333-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (100% higher). The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02357901 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02357901 about?
NCT02357901 is a clinical study titled "Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine". This is a randomized, double-blind, placebo controlled, multicenter study in male and female participants who are seeking treatment for opioid use disorder.
What is the current status of trial NCT02357901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2015-01-28. Estimated completion is 2016-04-29.
What conditions does trial NCT02357901 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Opioid Dependence.
What interventions are being tested in trial NCT02357901?
The interventions under investigation include: Placebo (DRUG), RBP-6000 (DRUG), SUBOXONE (DRUG).
Who is sponsoring clinical trial NCT02357901?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02357901 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
COMPLETED · Phase 3
-
Medication Treatment for Opioid Use Disorder in Expectant Mothers
COMPLETED · Phase 3
-
Buprenorphine Group Medical Visits in Primary Care
COMPLETED · Phase 3
-
Open-Label Treatment Extension Study
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.